Journal of Neuro-Oncology

, Volume 82, Issue 2, pp 207–209

A pilot study of primary temozolomide chemotherapy and deferred radiotherapy in elderly patients with glioblastoma

Clinical–Patient Studies

DOI: 10.1007/s11060-006-9269-z

Cite this article as:
Chamberlain, M.C. & Chalmers, L. J Neurooncol (2007) 82: 207. doi:10.1007/s11060-006-9269-z

Abstract

There is no standard of care for elderly patients (age ≥ 70 years) with newly diagnosed glioblastoma (GBM). In 15 consecutive patients (median age 79 years) treated with temozolomide (TMZ) (42 days on; 14 days off), median survival was 6 months (range 4–14 months). This pilot study suggests that low dose daily TMZ may represent an alternative and equally effective treatment to more traditionally administered radiotherapy.

Keywords

Elderly patients Glioblastoma Dose-dense temozolomide Deferred radiotherapy 

Copyright information

© Springer Science+Business Media, LLC 2006

Authors and Affiliations

  1. 1.Department of Interdisciplinary OncologyMoffitt Cancer Center and Research InstituteTampaUSA